Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression

Cell–cell adhesion mediated by ICAM-1 and VCAM-1 is critical for T cell activation and leukocyte recruitment to the inflammation site and, therefore, plays an important role in evoking effective immune responses. However, we found that ICAM-1 and VCAM-1 were critical for mesenchymal stem cell (MSC)-mediated immunosuppression. When MSCs were cocultured with T cells in the presence of T cell Ag receptor activation, they significantly upregulated the adhesive capability of T cells due to the increased expression of ICAM-1 and VCAM-1. By comparing the immunosuppressive effect of MSCs toward various subtypes of T cells and the expression of these adhesion molecules, we found that the greater expression of ICAM-1 and VCAM-1 by MSCs, the greater the immunosuppressive capacity that they exhibited. Furthermore, ICAM-1 and VCAM-1 were found to be inducible by the concomitant presence of IFN-γ and inflammatory cytokines (TNF-α or IL-1). Finally, MSC-mediated immunosuppression was significantly reversed in vitro and in vivo when the adhesion molecules were genetically deleted or functionally blocked, which corroborated the importance of cell–cell contact in immunosuppression by MSCs. Taken together, these findings reveal a novel function of adhesion molecules in immunoregulation by MSCs and provide new insights for the clinical studies of antiadhesion therapies in various immune disorders.

[1]  W. Weimar,et al.  Cell contact interaction between adipose‐derived stromal cells and allo‐activated T lymphocytes , 2009, European journal of immunology.

[2]  Yufang Shi,et al.  Species Variation in the Mechanisms of Mesenchymal Stem Cell‐Mediated Immunosuppression , 2009, Stem cells.

[3]  Yufang Shi,et al.  Apoptotic Cells Induce Immunosuppression through Dendritic Cells: Critical Roles of IFN-γ and Nitric Oxide1 , 2008, The Journal of Immunology.

[4]  Yufang Shi,et al.  Apoptotic Cells Induce Immunosuppression through Dendritic Cells: Critical Roles of Interferon‐gamma and Nitric Oxide , 2008 .

[5]  R. Zhao,et al.  Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell Stem Cell.

[6]  G. Lichtenstein Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial , 2008 .

[7]  Giselle Chamberlain,et al.  Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing , 2007, Stem cells.

[8]  A. Cope,et al.  The Antiproliferative Effect of Mesenchymal Stem Cells Is a Fundamental Property Shared by All Stromal Cells1 , 2007, The Journal of Immunology.

[9]  M. Haniffa,et al.  Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells1 , 2007, The Journal of Immunology.

[10]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[11]  R. Zhao,et al.  Immunosuppressive properties of cloned bone marrow mesenchymal stem cells , 2007, Cell Research.

[12]  Kazuya Sato,et al.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.

[13]  M. Yacoub,et al.  Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. , 2006, Tissue engineering.

[14]  G. D. De Keulenaer,et al.  Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. , 2006, American journal of physiology. Heart and circulatory physiology.

[15]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[16]  S. Okazaki,et al.  Characterization of Mesenchymal Stem Cells Isolated from Mouse Fetal Bone Marrow , 2006, Stem cells.

[17]  L. Moretta,et al.  Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. , 2006, Blood.

[18]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[19]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[20]  A. Lambiase,et al.  Upregulation of ICAM-1 Expression in the Conjunctiva of Patients with Chronic Graft-Versus-Host Disease , 2006, European journal of ophthalmology.

[21]  F. Benvenuto,et al.  Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.

[22]  O. Koç,et al.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.

[23]  Frank P Barry,et al.  Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.

[24]  Yi Zhang,et al.  Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. , 2005, Blood.

[25]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[26]  J. Harlan,et al.  Targeting leukocyte integrins in human diseases , 2005, Journal of leukocyte biology.

[27]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[28]  A. Straube,et al.  Cerebral Endothelial Expression of Adhesion Molecules in Mice with Chronic Graft-Versus-Host Disease , 2004, Stroke.

[29]  Y. Shimizu,et al.  Integrins and T cell-mediated immunity. , 2004, Annual review of immunology.

[30]  J. Pober,et al.  T lymphocyte-endothelial cell interactions. , 2004, Annual review of immunology.

[31]  L. Lindbom,et al.  Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. , 2003, Trends in pharmacological sciences.

[32]  L. Boulet,et al.  The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. , 2003, The Journal of allergy and clinical immunology.

[33]  J. Hunt,et al.  Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. , 2003, The Journal of trauma.

[34]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[35]  T. Tedder,et al.  L-Selectin or ICAM-1 Deficiency Reduces an Immediate-Type Hypersensitivity Response by Preventing Mast Cell Recruitment in Repeated Elicitation of Contact Hypersensitivity1 , 2003, The Journal of Immunology.

[36]  J. Mosca,et al.  Characterization and functionality of cell surface molecules on human mesenchymal stem cells. , 2003, Journal of biomedical science.

[37]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[38]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[39]  O. Guntinas-Lichius,et al.  Increased expression of ICAM-1, VCAM-1, MCP-1, and MIP-1α by spinal perivascular macrophages during experimental allergic encephalomyelitis in rats , 2002, BMC Immunology.

[40]  Xiaoping Liu,et al.  Nitric Oxide Uptake by Erythrocytes Is Primarily Limited by Extracellular Diffusion Not Membrane Resistance* , 2002, The Journal of Biological Chemistry.

[41]  A. Buchman,et al.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease , 2002, Gut.

[42]  Michael Loran Dustin,et al.  The immunological synapse , 2002, Arthritis research.

[43]  I. Campbell,et al.  Vascular cell adhesion molecule‐1 (VCAM‐1) blockade in collagen‐induced arthritis reduces joint involvement and alters B cell trafficking , 2002, Clinical and experimental immunology.

[44]  P. Smith,et al.  Proteins and lipids define the diffusional field of nitric oxide. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[45]  R. Fujinami,et al.  Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis , 1999, Journal of Neuroimmunology.

[46]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[47]  K. Salmela,et al.  A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. , 1999, Transplantation.

[48]  M. Isobe,et al.  Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. , 1997, Circulation.

[49]  Paul Wordsworth,et al.  A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. , 1997, British journal of rheumatology.

[50]  J. R. Lancaster A tutorial on the diffusibility and reactivity of free nitric oxide. , 1997, Nitric oxide : biology and chemistry.

[51]  A. Beaudet,et al.  Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. , 1996, Journal of immunology.

[52]  G. Sobue,et al.  Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats. , 1996, Cellular Immunology.

[53]  L. Davis,et al.  Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. , 1995, Journal of immunology.

[54]  M P Bevilacqua,et al.  Endothelial-leukocyte adhesion molecules. , 1993, Annual review of immunology.